Overview

Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma

Status:
Terminated
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
Assessment of safety and tolerability of ADI-PEG 20 in combination with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) in advanced GI malignancies.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Polaris Group